BI-9564

BI-9564 inhibits BRD9 and BRD7 bromodomains and exhibits no significant off-target pharmacology against a panel of 324 kinases and 55 GPCRs at concentrations less than 5 μM. BI-9564 is a selective inhibitor of BRD9 and BRD7 bromodomains (Kds = 14.1 and 239 nM; IC50s = 75 nM and 3.4 μM, respectively) that demonstrates cellular activity by semi-quantitative FRAP assay with ~90% inhibition of BRD9 and BRD7 at 0.1 μM and 1 μM, respectively. Inhibits proliferation of AML cell lines in vitro and reduces AML tumor xenograft growth in vivo.